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PENILAIAN IN VITRO DAN PRAKLINIKAL VIRUS SAMPAR AYAM 
STRAIN V4UPM SEBAGAI CALON VIRUS ANTIKANSER UNTUK 
TERAPI NOVEL BAGI GLIOMA MALIGNAN MANUSIA 
ABSTRAK 
Virus pemusnah kanser merupakan virus aktif yang digunakan untuk menjangkiti sel 
kanser dan telah dikaji dengan meluas bagi tujuan rawatan kanser. Virus pemusnah 
kanser menjangkiti sel kanser secara spesifik kerana virus ini mampu 
mengeksploitasi mutasi yang merangsang pembiakan sel kanser tanpa menjejaskan 
sel yang normal. Kanser otak adalah malignan pembunuh didalam otak dan glioma 
merupakan kanser otak manusia yang bertumbuh dari sel glia dan ianya paling kerap 
dijumpai. Glioma tahap IV dikenali sebagai glioblastoma multiform (GBM) dimana 
pembiakan dan perebakan GBM ini dikaitkan dengan peningkatan ekspresi protin 
Rac1. Virus sampar ayam (NDV) adalah virus avian didalam keluarga 
paramyxovirus, dan merupakan salah satu virus pemusnah kanser yang mewarisi 
seleksi terpilih terhadap sel kanser. NDV dilaporkan menjadi pencetus kepada 
pembentukkan sel syncytia dan mengaruh bagi kematian sel didalam pelbagai jenis 
kanser, tetapi dilaporkan selamat untuk suntikan klinikal pada manusia. Didalam 
kajian ini, NDV strain V4UPM telah dikaji sebagai perangsang untuk mematikan sel 
glioma. Kesan ketoksikan V4UPM dan mekanisma molekular pada GBM terawat 
telah diuji pada model in vitro menggunakan ujikaji microtetrazolium (MTT), ujikaji 
kematian sel, teknik pengimejan langsung, mikroskopi fluorescence dan western 
blot. Ianya juga diuji pada model mencit bogel (in vivo) dan ex vivo. Penemuan kami 
telah membuktikan V4UPM pada dos 9 HAU telah mencetus kematian sel barah otak 
manusia dimana permulaan pemusnahan sel ini berlaku kurang dari 12 jam selepas 
rawatan, selain ianya tidak menjejaskan sel astrocyte normal (p>0.05). Analisis 
xvii 
 
melalui kaedah pengimejan 3 dimensi pada NDV dan tetulang sel menunjukkan 
kemungkinan kemasukan virus didalam sel barah ini adalah melalui mekanisma 
pembenaman caveole. Analisis seterusnya melalui pewarnaan immunofluorescence 
menunjukkan jangkitan V4UPM telah merangsang penyusunan semula struktur 
tetulang pada sel membentuk synsytia dan dikaitkan dengan peningkatan ekspresi 
protin Rac1 serta protin NFKB pada fasa awal jangkitan. Walaubagaimanapun, 
ekspresi protein ini menurun selepas 12 jam. Analisa praklinikal pada model glioma 
didalam mencit bogel dengan system imun yang gagal berfungsi sepenuhnya telah 
menunjukkan kemampuan V4UPM pada dos 520 HAU untuk mengaruhkan 
pengecutan ketulan glioma tersebut (p<0.05), selain tidak merangsang ketoksikan 
kepada hos (p>0.05). Potensi V4UPM seterusnya diuji pada hirisan glioma liar yang 
diperolehi dari pesakit hospital Universiti Sains Malaysia dan penemuan 
menunjukkan rawatan ini mengaruhkan kematian sel secara signifikan (p<0.05) 
selepas 48 jam rawatan. Sebagai konklusi, NDV dilihat mengekploitasi aktin pada sel 
untuk pembenaman virus dan mengaruh penggabungan sel serta penyusunan semula 
tetulang sel yang seterusnya memanjangkan hayat sel yang dijangkiti, namun selepas 
seketika sel tersebut mengalami kemusnahan. Penemuan praklinikal pula 
menunjukkan potensi terapeutik V4UPM pada GBM dalam model haiwan dan model 
ex vivo serta ianya selamat digunakan. Keseluruhanya, V4UPM adalah calon yang 
bertepatan untuk kajian selanjutnya didalam model haiwan bukan tikus dan primat 
sebagai terapi baru bagi barah otak manusia.  
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IN VITRO AND PRECLINICAL EVALUATION OF NEWCASTLE DISEASE 
VIRUS STRAIN V4UPM AS AN ONCOLYTIC VIRUS CANDIDATE FOR 
NOVEL HUMAN MALIGNANT GLIOMA THERAPY 
ABSTRACT 
Oncolytic viruses are replicating viruses that have been used to infect neoplastic cells 
and are widely studied as a form of antitumor therapy. Oncolytic viruses specifically 
target tumorigenic cells because they are able to exploit the aberrations on the 
cellular level that promote tumor growth and the viruses preferentially infect cancer 
cells without interfering with normal cells. Brain cancer is a malignant growth within 
the skull and glioma is the most common human brain cancer arising from glial cells. 
Grade IV glioma is known as glioblastoma multiforme (GBM) where the 
proliferation and invasive behavior in GBM was associates with upregulation of 
Rac1 protein. Newcastle disease virus (NDV), an avian virus in the Paramyxovirus 
family, is one of the oncolytic viruses that inherit natural selectivity towards cancer. 
It is reported to robustly induce syncytium and apoptosis in multiple types of cancer 
cells but found to be safe for clinical injection into human. In this study, the NDV 
strain V4UPM has been evaluated as a potential agent for brain cancer therapy. The 
cytotoxicity and molecular mechanism of V4UPM effects on GBM was evaluated in 
in vitro model using microtetrazolium (MTT) assay, apoptosis assay, live cell 
imaging, fluorescence microscopy and western blot technique. The oncolytic NDV 
induce GBM regression were also evaluated in in vivo and ex vivo models. Findings 
have shown that V4UPM at 9 HAU induces the apoptosis of human brain cancer 
cells with the onset of cytolysis occurring less than 12 hours after infection. Besides, 
it is non-toxic to normal human astrocytes cell lines (p>0.05). The three-dimensional 
imaging analysis of NDV co-localization with the actin cytoskeleton revealed a 
xix 
 
potential of caveolae-mediated endocytosis as a viral entry mechanism. V4UPM 
infection also led to the reorganization of the actin cytoskeleton in syncytium cells 
and was associated with the upregulation of Rac1 and NFKB proteins in early phase 
of infection, but subsequently downregulated after 12 hours. Preclinical evaluation in 
immune-compromised athymic nude mice revealed that V4UPM at 520 HAU could 
induce the subcutaneous regression (p<0.05) of homogenous glioma xenografts 
without inducing any acute toxicity (p>0.05) in the host. V4UPM was subsequently 
tested on ex vivo heterogeneous glioma slices obtained from Hospital Universiti 
Sains Malaysia patients and found to decrease (p<0.05) of tissue viability 48 hours 
after treatment. In conclusion, V4UPM seems to exploit cellular actin for viral entry 
and induces actin reorganization to sustain replication via the Rac1 signaling 
pathway, subsequently inducing apoptosis. Preclinical study demonstrates the 
therapeutic potential of V4UPM against GBM in in vivo and ex vivo with a 
promising safety margin. Therefore, V4UPM is found to be a potential candidate for 
subsequent analyses in non-rodent models and non-human primate as novel therapies 
for human brain tumors. 
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CHAPTER ONE 
INTRODUCTION 
Glioma is a tumor of the central nervous system arising from glial cells, and 
grade IV glioma is known as glioblastoma multiforme (GBM). GBM is the most 
common adult primary brain tumor, with relatively low incidence compared to other 
types of tumors. Approximately 22,070 new cases of central nervous system tumors 
occurred in the United States in 2009, representing 1.5% of all tumor sites (Jemal et 
al., 2009). In Malaysia, the National Cancer Registry report in 2006 showed that the 
incidence of all types of cancers are estimated as 1 in 4, whilst the incidence of brain 
and nervous system tumors is 3.3 per 100,000 people (CR) in 2006 (Omar et al., 
2006; Farooqui et al., 2013; Mustafa et al., 2013). Even though the brain and nervous 
system tumors does not even account for the top ten local cancers, the GBM shows 
rapid development, and its median survival of only 12-15 months has remained 
unchanged for 25 years with almost 100% mortality (Zemp et al., 2010; Zhong et al., 
2010; Wollmann et al., 2012). For this reason, GBM is also aptly called The 
Terminator (Holland, 2000). 
Decades of studies revealed that tumorigenesis is a multistep process in 
which mutations in tumor suppressors and proto-oncogenes accumulate (Biederer et 
al., 2002; Nakada et al., 2011), thus deregulating normal cellular signaling and the 
cell cycle. These mutations lead to the self-sufficiency of growth signals, 
insensitivity to anti-growth signals, deregulated proliferation, escape from the 
apoptosis pathway, enhanced angiogenesis and the acquisition of invasive properties 
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(Conti et al., 2010). All of these defects are associated with specific gene or pathway 
alterations, which occur in gliomagenesis and sustain malignant progression 
(Krakstad and Chekenya, 2010). In particular, several oncogene aberrations have 
been reported in GBM, such as the amplification of epidermal growth factor 
receptors (EGFR) and the activation of the receptor tyrosine kinase (RTK) family, 
PI3K, and NFKB (Nakada et al., 2011).  
In addition, a pathway that is less emphasized but has exhibited remarkable 
and important aberrations in GBM is overexpression of Rac1 protein. This protein 
signalling controls proliferation and regulates autonomous behavior in GBM 
(Gjoerup et al., 1998; Chan et al., 2005; Michaelson et al., 2008; Bosco et al., 2009). 
Rac1, known as Ras-related C3 botulism toxin substrate 1, is a member of the 
monomeric G-protein Rho GTPases. This protein is involved in the regulation of the 
cell cytoskeleton, migration, gene transcription, and G1 cell-cycle progression 
(Senger et al., 2002; Villalonga et al., 2004; Sun et al., 2006). Former studies have 
reported that the suppression of Rac1 leads to glioma inhibition (Senger et al., 2002). 
Thus, novel treatments have focused on exploiting this aberration in GBM (Kanu et 
al., 2009), notably in dealing with the obstacles encountered in temozolamide 
resistant GBM (Bredel et al., 2011).  
Oncolytic viruses have been extensively evaluated, due to their potential to 
infect cancer cells preferentially without interfering with normal cells (Parato et al., 
2005; Liu et al., 2007; Parker et al., 2009; Wollmann et al., 2012).  Taking 
advantage of the genetic defects or aberrations that fuel cancer growth, targeted 
therapy using oncolytic viruses to kill cancer cells with genetic defects or mutations 
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was investigated. Viruses with oncolytic properties and limited side effects were 
used as miniature biological machines to reach the targeted cancer cells. 
Newcastle disease virus (NDV) is an avian pathogen that exhibits selective 
oncolytic properties and is one of the most intensively studied oncolytic viruses, 
affecting many types of human cancer. NDV is a single-stranded negative-sense 
avian RNA virus in the family of Paramyxovirus that inherits selective oncolytic 
properties (Sinkovics and Horvath, 2000) . The virus encodes six viral proteins in the 
order 3’-NP-P-M-F-HN-L-5’ and has been divided into three pathotypes according to 
pathogenicity: velogenic, mesogenic and lentogenic  (Schirrmacher and Fournier, 
2009). The cells that are infected by NDV undergo cell-cell fusion, which is called 
syncytium formation (Zamarin and Palese, 2012). 
To date, several replication-competent strains of NDV have been tested for 
their oncolytic capacities in phase II clinical trials, including the MTH-68 and HuJ 
strains (Freeman et al., 2006; Yaacov et al., 2008). NDV is reported to be safe for 
injection into human (Zemp et al., 2010). Other strains, such as 73-T (Phuangsab et 
al., 2001), PV-701 (Pecora et al., 2002), Ulster (Fiola et al., 2006), Beaudette C 
(Krishnamurthy et al., 2006), AF2240 (Meyyappan et al., 2003) and V4UPM 
(Zulkifli et al., 2009), are currently being investigated for their oncolytic potential at 
a preclinical level. 
In particular, the V4UPM strain is a modified avirulent V4 strain that has 
been cloned as a thermostable virus and used as feed pellet vaccine for poultry in 
Malaysia and Nigeria (Ideris et al., 1990; Nwogu and Olaji, 2012). Study has also 
indicates that V4UPM induces apoptosis in a glioma cell line (Zulkifli et al., 2009). 
Nevertheless, the fundamental mechanism that drives NDV infection in tumorigenic 
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cells remains to be elucidated. Recently, a study showed that Rac1 was required for 
NDV replication in human cancer cells, and this finding established a link between 
tumorigenesis and sensitivity to the oncolytic virus (Puhlmann et al., 2010). In 
Puhlmann et al.,(2010) the dynamic siRNA approach using the skin carcinoma 
HaCaT cell line and Rac1 knockdown with two different siRNAs led to the 
significant inhibition of viral replication, thereby demonstrating that Rac1 protein is 
an essential component of efficient NDV replication in tumorigenic cells.  
The primary aim of this thesis is to evaluate the potential of NDV V4UPM as 
an oncotherapeutic virus against human brain cancer in in vitro, in vivo and ex vivo 
experimental settings. In in vitro studies, the cytotoxic dose of V4UPM on GBM 
cells was determined and observed the temporal morphological changes of infected 
GBM cells by live cell imaging. The Annexin V apoptosis assay was performed to 
determine the mode of infected cell death, and the expression of Rac1 and NFKB 
proteins was monitored in GBM following the V4UPM treatment. As the Rac1 
protein primarily regulates the actin cytoskeleton of the cells, actin was also 
visualized at an early phase of cell infection. 
For in vivo study, the preclinical antitumor potential of V4UPM was tested 
on the subcutaneous xenograft glioma model in nude mice, and the acute toxicity 
was evaluated as a safety measurement. Finally, an ex vivo study was performed to 
evaluate the effects of V4UPM infection on authentic GBM obtained from patients in 
Universiti Sains Malaysia hospital, and V4UPM infectivity was evaluated in human 
cerebral spinal fluid (CSF) media (Mustafa et al., 2013). All of these analyses were 
designed to address the general objective to determine the potential of V4UPM as a 
safe and potent oncotherapy for human brain cancer. 
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CHAPTER TWO 
LITERATURE REVIEW 
2.1 Oncolytic viral therapy 
2.1.1 Definition 
Oncolytic viruses are viruses that selectively eradicate tumor cells without 
harming the normal surrounding tissues (Biederer et al., 2002; Russell, 2002; Zemp 
et al., 2010). Oncolytic viruses are used to recognise and infect mutated cancerous 
cells, where they replicate and then release new virions that amplify the input dose. 
Newly produced virions can also spread and infect the adjacent cancerous cells. 
Consequently, infected cells often undergo pathological programmed cell death 
known as apoptosis. Infected cells are also targeted by the host immune system. 
Selective oncolysis can be caused by naturally occurring viruses that inherit 
oncolytic properties or by genetically modified viruses that only target cancer cells 
by design.  
Viruses have also been used as a vehicle for nucleic acid transfer (Parker et 
al., 2009). These viral vectors are intended to re-establish the wild-type copies of 
mutated tumor suppressor genes in cancer, affect the metabolism of tumor cells, 
activate the host immune response, or sensitize the neoplastic tissue to standard 
therapies (Cervantes-Garcia et al., 2008). These methods are all within the field of 
gene therapy. In summary, viruses with oncolytic properties and limited side effects 
were used as miniature biological machines to reach the targeted cancer cells and 
lead to cancer cell death (Russell, 2002; Zamarin and Palese, 2012). 
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2.1.2 History of oncolytic virus therapy 
Oncolytic viruses were noted as early as 1912, when a female patient 
suffering from cervical carcinoma showed significant tumor shrinkage after being 
vaccinated against rabies. The attenuated rabies vaccine was administered as a 
prophylactic treatment following a dog bite (Nemunaitis, 1999). 
Further reports of the regression of Burkitt’s and Hodgkin’s lymphomas were 
documented after natural infection by the measles virus. Later, several potential 
oncolytic viruses were proposed for clinical trials in the 1950s (Everts and van der 
Poel, 2005). Summarized by Kelly et al (Table 2.1), five significant virotherapy 
clinical trials were reported: Hodgkin’s disease was treated with Hepatitis B virus in 
1949, “unresponsive neoplastic disease” was treated with West Nile virus in 1952, 
cervical carcinoma was treated with adenovirus in 1956 and terminal cancers were 
treated with the wild type non-attenuated mumps virus in 1974 (Kelly and Russell, 
2007). In a revised timeline, the first virus-induced tumor recovery was reported in 
chronic myeloid leukemia as early as 1904 (Liu et al., 2007).  
Even though oncolytic potential was present in some cases, official analyses 
demonstrated a lack of the desired anticancer activities. Therefore, this therapy was 
abandoned for almost two decades. Modern knowledge of the basic principles of 
molecular biology, including cell cycle control and cell death, tumorigenesis, viral 
biology and the discovery of recombinant DNA technology in the intervening years 
have resulted in the current revival of oncolytic viruses as a form of cancer therapy 
(Everts and van der Poel, 2005; Todo, 2008). These advances led to the first trials 
with engineered oncolytic viruses in the 1990s. 
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With respect to human brain cancer, the preclinical studies of oncolytic 
viruses in glioma emerged in the 1990s, when the first attenuated herpes simplex 
viruses (HSVs) and adenoviruses were used, followed by oncolytic reoviruses. To 
date, four viruses have completed the clinical trials: herpes simplex virus (strains 
HSV-1, HSV-1716 & HSV-G207), Newcastle disease virus (strains MTH-68/H, 
NDV-Huj), adenovirus (Onyx-015) and reovirus. From the phase 1 trials, the viruses 
were declared as safe to be injected directly to the brain, and no maximum tolerated 
dose (MTD) was reached. Some anti-glioma activities were also observed. Among 
these, NDV had the most promising benefits, as six patients exhibited tumor 
regression and 3 patients exhibited long-term survival (Zemp et al., 2010).  
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Table 2.1 Five significant historical virotherapy clinical trials against human cancer. 
Modified from (Kelly and Russell, 2007) 
 
 
Year 
 
Disease 
 
Virus 
 
No of 
patients 
 
 
Route 
 
Outcome 
 
Side effects 
 
1949 
 
Hodgkin’s 
disease 
 
Hepatitis B 
virus 
 
22 
 
Parenteral 
injection of 
unpurified 
human serum 
 
7/22 improve 
in clinical 
aspect of 
disease and 
4/22 reduction 
in tumor size 
 
 
Fever, 
malaise, 
death 
1952 Advance 
unresponsive 
neoplastic 
disease 
Egypt 101 
virus (early 
passage 
West Nile) 
34 IV, IM injection 
of 
bacteriologically 
sterile mouse 
brain, chick 
embryo, human 
tissue 
 
27/34 infected, 
14/34 
oncotropism 
and 4/34 
transient 
regression 
Fever, 
malaise, mild 
encephalitis 
1956 Cervical 
carcinoma 
Adenovirus 
adenoidal-
pharyngeal-
conjuctival 
virus (APC) 
 
30 IT, IA, IV 
injection of TC 
supernatant 
26/40 
inoculation 
resulted in 
localized 
necrosis 
Vaginal 
haemorrhage, 
infrequent 
fever (3/30), 
malaise 
1964 
 
Myelogenous 
Leukaemia 
 
NDV 1 IV “responded to 
treatment” 
No 
description 
1974 Terminal 
cancers; 
gastric, 
pulmonary, 
uterine  
Mumps 
virus (wild-
type, non-
attenuated) 
90 IT, IV, oral, 
rectal; inhalation 
of purified 
human saliva or 
TC supernatant 
37/90 
complete 
regression or 
decrease 
>50%, 42/90 
decrease 
<50%, and 
11/90 
unresponsive 
7/90 adverse 
reactions; 
bleeding 
fever 
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2.1.3 Classification of oncolytic viruses 
The oncolytic viruses are divided in two groups according to their nature: 
naturally occurring viruses with innate oncolytic activity and engineered viruses that 
alter specific genes by design to achieve selective oncolysis (Cervantes-Garcia et al., 
2008). The viral modifications in engineered viruses were also intended to attenuate 
their pathogenicity. 
Summarized in Figure 2.1, viruses in cancer therapy are also divided into 
replication-defective viruses and replication-competent viruses. Most of the naturally 
occurring viruses are replication competent. In contrast, replication-defective viruses 
may also be used in oncotherapy as carriers of gene therapy through suicide gene 
delivery to targeted cells (Biederer et al., 2002; Prestwich et al., 2008). The suicide 
genes can be prodrug activating enzymes, death genes, tumor suppressor genes or 
antisense against oncogenes (Biederer et al., 2002; Liu and Kirn, 2008). 
NDV, reovirus, bovine herpes virus 4, coxsackie virus, vesicular stomatitis 
virus (VSV) and parvovirus are examples of natural viruses with innate oncolytic 
activity against human tumors (Cervantes-Garcia et al., 2008).  
Viruses were also enhanced with genetic modification to improve their 
selectivity by the insertion or deletion of therapeutic transgenes (Stanford et al., 
2010). Viruses can be made tumor selective by the modification of cellular tropism at 
the level of viral replication such that they become dependent on the specific 
characteristics of tumor cells. This specificity can be achieved by deleting viral genes 
that are critical for viral replication in healthy cells but are dispensable upon the 
infection of neoplastic cells. The modification of cellular tropism at the level of cell 
recognition and binding can be achieved by altering the viral coat for tumor-selective 
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binding and uptake (Everts and van der Poel, 2005; Russell et al., 2012). Adenovirus, 
HSV and vaccinia virus are DNA viruses that have been modified using recombinant 
technology to attenuate their pathogenicity (Prestwich et al., 2008). 
Despite the direct cytolysis of cancerous cells, oncolytic viruses also 
stimulate the inflammatory response (Fournier et al., 2012). The virally induced lysis 
of carcinogenic cells will release a wide range of tumor-associated antigens (TAAs). 
These TAAs will be processed by infiltrating dendritic cells and migrating to the 
lymphatic system, cross-presenting antigens to T cells, and potentially generating an 
adaptive anticancer immune response (Prestwich et al., 2008). 
For example, the most common immune-modulatory protein inserted into the 
oncolytic viruses is the granulocyte-macrophage colony-stimulating factor (GM-
CSF), which has been inserted into adenovirus, herpes simplex virus and vaccinia 
virus to stimulate an inflammatory response within the tumor microenvironment 
(Stanford et al., 2010) and lead to cancer cell death.  
In contrast, the replication cycles of RNA viruses are not subject to the 
mechanism of nuclear transcription factors and must rely on a different pathway for 
their replication selectivity in cancerous cells. RNA virus life cycles involve the 
formation of dsRNA, which activates a spectrum of infected cellular defense 
mechanisms, including the activation of PKR and the release of interferons. The 
most promising oncolytic RNA viruses currently documented are attenuated strains 
of reovirus, measles virus, VSV, NDV, mumps virus, influenza virus and polio virus 
(Russell, 2002; Liu and Kirn, 2008; Russell et al., 2012). 
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Examples of virus as a vector 
 
 Direct viral oncolytic tropism 
Pro-drug 
activating 
enzymes 
Death 
genes 
Tumor 
suppressors 
Anti-
sense 
against 
oncogenes 
Virus with 
deletion in 
viral genes 
Tumor & tissue 
specific 
regulatory 
elements driving 
essential viral 
genes 
Wild-
type 
virus 
 
 
Figure 2.1 Applications of viruses for oncotherapy. Viruses can be used as vectors 
for therapeutic molecules (Group I) or used for the direct selective oncolysis of 
cancerous cells (Group II). Modified from Biederer et al., (2002) 
 
 
 
 
 
 
 
Therapeutic 
virus 
Replication-
competent Viruses 
Replication-
defective Viruses 
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2.1.4 Characteristic of oncolytic viruses  
Taking advantage of the genetic defects that fuel cancer growth, targeted 
therapies using oncolytic viruses to kill cancer cells with genetic defects or 
aberrations offer tremendous therapeutic potential. The modern era of cancer therapy 
research is now moving toward “biological weapons” that have evolved in parallel 
with cancer cells. 
Several features are required for oncolytic viruses to be used as an effective 
cancer treatment (Biederer et al., 2002; Parato et al., 2005; Liu and Kirn, 2008; 
Parker et al., 2009; Zemp et al., 2010; Wollmann et al., 2012) which include: 
I. The virus is not a human pathogen but is capable of infecting human 
cells. This property will reduce the likelihood of pre-existing immunities 
against the vectors that would limit their therapeutic effectiveness 
(Zamarin and Palese, 2012). 
II. Limited side effects to human (Zamarin and Palese, 2012). 
III. Applicable for recombinant technology, such as the introduction of 
suicide genes into transformed cells and the insertion of transgenes for 
monitoring of viral shedding (Wollmann et al., 2012). 
IV. The viral life cycle of replication-competent viruses should include rapid 
replication and spread to induce cytolysis. This accelerated life cycle will 
facilitate the amplification of the viral therapeutic dose (Russell et al., 
2012). 
V. The oncolytic viruses should be able to tolerate systemic administration 
(Russell et al., 2012). 
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VI. The virus should not only eradicate the transformed cells but should also 
be able to establish anti-tumor immunity and should allow the virus to act 
as a potent anticancer vaccine adjuvant (Zamarin and Palese, 2012). 
VII. The virus should not enter the nucleus or recombine with the host cell 
genome. This property will minimize the risk of virus-host genetic 
recombination events (Zamarin and Palese, 2012). 
VIII. Selective replication should occur in transformed cells, sparing the non-
transformed normal cells (Zamarin and Palese, 2012). 
IX. Potential for high-titer virus production, simple and safe manufacturing. 
X. The availability of specific antiviral agents is necessary to help regulate 
the viral distribution (Russell et al., 2012).  
XI. Viruses that demonstrate efficacy in the treatment of tumors can be used 
clinically in combination with standard treatment modalities (Parker et 
al., 2009). 
2.1.5 Advantages of oncolytic viruses 
An ideal oncolytic virus for cancer therapy offers numerous advantages. The 
therapeutic benefits of this emerging therapy include natural selectivity during virus 
infection, which allows the viruses to selectively infect mutated cancer cells and 
helps to spare the normal tissue. Therefore, the viruses do not adhere to conventional 
toxicity and dose-response relationships (Biederer et al., 2002; Wollmann et al., 
2012). 
Oncolytic viruses are also “engineerable”. If they are not already naturally 
discriminatory, oncolytic viruses can be genetically engineered to be selective for 
mitotically active neoplastic cells. This property is especially appealing for glioma 
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therapy, as the tumor-adjacent, quiescent neurons often remain resistant and intact 
after treatment. Additionally, oncolytic viruses enable the introduction of therapeutic 
genes, allowing them to act as vectors for the augmentation of specific antitumor 
effects (Aghi and Chiocca, 2006; Zemp et al., 2010; Wollmann et al., 2012).  
Moreover, oncolytic viruses theoretically offer unique pharmacokinetics, as 
the input dose can be amplified following viral replication. Current findings also 
show that along with current conventional treatments, the virotherapeutics have 
demonstrated synergy with approved chemotherapeutics and radiotherapy (Zemp et 
al., 2010). For example, oncolytic adenovirus has been intratumorly injected along 
with docetaxel for treatment of prostate cancer (Russell et al., 2012)    
Furthermore, several oncolytic viruses have passed phase I clinical trials, and 
the results indicate that most of the oncolytic viruses are safe for direct 
administration into humans (Biederer et al., 2002; Parato et al., 2005; Cervantes-
Garcia et al., 2008; Liu and Kirn, 2008; Russell et al., 2012). 
2.1.6 Disadvantage of oncolytic viruses 
Conversely, some oncolytic viruses operate optimally using cell-cell contact 
to assist viral spread. An oncolytic virus entering a normal cell triggers the cellular 
antiviral response but cannot counterattack, so the infection is quickly eliminated 
(Russell et al., 2012).  
In the case of GBM, for example, single-cell infiltration into the normal cell 
population is thought to be a major obstacle because viral proliferation could be 
inhibited by the surrounding normal tissue. Therefore, the objective of targeting 
multifocal tumors in the brain might be difficult (Zemp et al., 2010).  
15 
 
In addition, circulating antibodies potentially neutralize free virus, and the 
rapid loss of oncolytic cells may entirely negate the therapeutic potential (Russell, 
2002; Russell et al., 2012). Therefore, the therapeutic index and ultimately the 
clinical outcome will depend on a complex balance between the host and viral factors 
(Biederer et al., 2002; Liu and Kirn, 2008).  
Moreover, DNA viruses can potentially undergo genetic shift or drift and thus 
can evolve over time. Thus, working with these viruses could become a major 
hurdle, specifically in terms of inducing the genotoxic effects (Liu and Kirn, 2008).   
2.1.7 Current oncolytic virus candidates in trials on various cancers 
Oncolytic viruses have several features that are unique from other 
therapeutics. Specific properties or features of the viruses determine different targets 
on the cancerous cells. The molecular aberrations of many cancerous cells are widely 
distinct. Therefore, several viruses have been screened for their oncolytic 
capabilities. In the past decade, the oncolytic viruses have been tested on various 
human cancer cells in vitro and in animal models with very promising benefits 
(Schirrmacher and Fournier, 2009; Zamarin and Palese, 2012).  
Nevertheless, the studies conducted are not limited to replication-mediated 
oncolysis only but have also been evaluated for anti-tumor immune induction, anti-
angiogenesis, and the induction of apoptosis and autophagy (Liu and Kirn, 2008). 
Some of the viruses that have been evaluated against multiple types of cancers 
include adenovirus, reovirus, HSV1, NDV, vaccinia virus, coxsackie virus, measles 
virus, VSV, retrovirus and myxoma virus (summarized in Table 2.2) (Parato et al., 
2005; Wollmann et al., 2012). 
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Table 2.2 Oncolytic viruses, their mechanisms and the phase of studies in all targeted 
tumor cells that underwent trials. Modified from Parato et al., (2005).  
 
Virus Mechanism  of tumor 
targeting 
Phase of 
development 
 
Types of Cancer 
Adenovirus Targets to tumor antigens; 
conditionally replicating 
 
Phase III 
conducted 
Squamous head and 
neck carcinoma 
Reovirus Selectively infect Ras-
transformed cells 
 
Phase I 
conducted 
Melanoma and 
malignant glioma 
Herpes 
Simplex virus 
1 (HSV-1) 
 
Only replicates in tumor cells Phase I 
conducted 
Glioma 
Newcastle 
Disease virus 
Selectively replicates in 
interferon defective cells 
 
Phase I 
conducted 
Advance Solid 
cancers 
Vaccinia virus Gain access to tumor by 
vascular leakiness 
 
Phase I 
conducted 
Melanomas 
Coxsackie-
virus 
Selectively infects tumor 
cells that over express DAF 
 
Phase I 
conducted 
Melanoma 
Measles virus Virus re-targeting to tumor 
antigens; overexpression of 
virus receptor (CD46) on 
some tumor cells 
 
Phase I ongoing Ovarian cancer 
Vesicular 
Stomatitis 
virus 
 
Selectively replicates in 
interferon defective cells 
 
Preclinical 
mouse model 
Metastatic tumor 
Influenza virus Non-structural protein 1-
deleted virus specifically 
replicate in interferon 
defective cells 
 
Preclinical 
mouse model 
Tumorous cell 
Retro virus Tumor specific promoter 
allows expression only in 
cancer cells 
 
Preclinical 
mouse model 
Tumorous cell 
Myxoma virus Replicates selectively in 
signal transducer and 
activator of transcription 1 
(STAT-1) or interferon 
defective cells 
In vitro study Tumorous cell 
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2.1.8 Oncolytic viruses on brain cancer 
Brain cancer is the malignancy found in the brain parenchyma, where grade 
IV brain cancer is characterized as GBM. As malignant GBM is among the few 
rapidly proliferating tumors of the central nervous system, it is becoming an 
interesting subject for the study of selective-amplification viruses (Aghi and Chiocca, 
2006; Mustafa et al., 2011).  
A review by Parker et al. in 2009 explained that the modern oncolytic 
targeted therapy has been initiated by engineered replication-attenuated viruses in 
non-dividing cells, such as neurons. The HSV with thymidine kinase deleted, dlsptk, 
has been designed for this purpose. The deletion of the tk gene controls the virus by 
making it dependent on actively dividing cells for its supply of both thymidine kinase 
and nucleotide pools for DNA replication. In animal studies, the dlsptk mutant virus 
exhibits a favorable therapeutic benefit in the treatment of glioma (Parker et al., 
2009). Unfortunately, the inactivation of the tk gene also renders this mutant resistant 
to acyclovir, an antiviral agent that targets the viral thymidine kinase. This antiviral 
resistance prevented further evaluation of this modified virus in clinical trials (Parker 
et al., 2009).  
To date, members of various virus families with distinctly different biologies 
have been tested on human GBM. Several modern clinical trials have been initiated 
for different oncolytic viruses (Parker et al., 2009; Russell et al., 2012). Wollmann et 
al. (2012) has reviewed all the clinical trials that had been initiated using attenuated 
strains and results from the trials have clearly established the proof of concept and 
have confirmed the general safety of oncolytic virus application in the brain 
(Wollmann et al., 2012).  
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A total of fourteen virus families that target human glioma have been tested 
(summarized in Table 2.3). The viruses are HSV, adenovirus, reovirus, NDV, 
measles virus, vaccinia virus, myxoma virus, poliovirus, VSV, parvovirus, sindbis 
virus and SVV. Among these, HSV, adenovirus, reovirus and NDV have completed 
the early phase clinical trials in brain cancer patients (Table 2.4) (Zemp et al., 2010). 
The findings of all phase I clinical trials, which were conducted with the 
primary goal of evaluating the safety of oncolytic viruses, were largely successful.  It 
was reported that these viruses were nontoxic and safe, with no maximum tolerate 
dose MTD reached. Although efficacy is not a major objective of this phase, some 
anti-glioma activity was observed in a handful of the subjects. These preliminary 
studies have demonstrated that the live replication-competent viruses can be safely 
administered into the brains of GBM patients (Zemp et al., 2010). 
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Table 2.3 List of oncolytic virus candidates that have been evaluated in the context of 
human brain cancer in preclinical and clinical trials. Extracted from Wollmann et al., 
(2012). 
 
Oncolytic Virus Candidates for Glioma Therapy With Summary of Tumor Selectivity Factors 
Virus 
 
Genome 
and 
Structure 
 
Host and 
Virus 
Family 
 
Determinants for Tumor-Selective 
Targeting or Replication 
 
Progress 
Relating 
to 
Glioma 
HSV-1 ds DNA 
Enveloped 
Human 
Herpes-
viridae 
(1) HSV-TK and RR mutations compensated 
by activated cell cycle in tumors. 
(2) PKR defects in tumors allow F134.5 
deleted HSV to replicate. 
(3) ICP47 gene deletion acts immune-
stimulatory 
Clinical 
phase I/II 
NDV ss (-) RNA 
Enveloped 
Avian 
Paramyxo-
viridae 
(1) Mainly induction of anti-tumor cytokines 
and immune response 
(2) Possibly exploiting IFN defects 
Clinical 
phase I/II 
Adeno-
virus 
ds DNA 
Naked 
Human 
Adeno-
viridae 
(1) Defects in p53 or RB pathway targeted by 
E1B and E1A mutants 
(2) RGD modification targets tumor integrins 
(3) E2F1 responsive elements control viral 
replication 
Clinical 
phase I 
Reovirus ds RNA  
Naked 
Mammalian 
Reoviridae 
(1) Tropism for Ras-activated, transformed 
tumor cells 
Clinical 
phase I 
Vaccinia ds DNA 
Enveloped 
Cow/horse 
Poxviridae 
(1) TK deletion compensated by nucleotide 
abundance in transformed tumors 
(2) VGF deletions compensated by aberrant 
EGFR receptor activation 
(3) Large size requires leaky tumor vessels for 
viral extravasation 
Pre-
clinical 
in vivo 
Polio ss (+) 
RNA 
Naked 
Human 
Picorna-
viridae 
(1) Polio receptor CD155 expressed on glioma 
(2) Pathogenic polio IRES replaced with 
rhinovirus IRES 
Clinical 
phase I 
VSV ss (-) RNA 
Enveloped 
Livestock 
/mosquito 
Rhabdoviridae 
(1) Selective replication depends on defective 
IFN pathway in tumor cells 
Pre-
clinical 
in vivo 
MVM ss DNA 
Naked 
Mouse 
Parvoviridae 
(1) Actively dividing cells required for 
replication 
(2) Defects in PKR augment viral replication 
Pre-
clinical 
in vivo 
Sindbis ss (+) 
RNA 
Enveloped 
Mammalian/ 
mosquito 
Togaviridae 
(1) Sindbis binds to 67-kd laminin receptor, 
which is overexpressed on some tumors 
Pre 
clinical 
in vivo 
PRV ds DNA 
Enveloped 
Pig Herpes-
viridae 
(1) HSV-TK and RR mutations compensated 
by activated cell cycle in tumors 
Pre-
clinical 
in vivo 
Measles ss (-) RNA 
Enveloped 
Human 
Paramyxo-
viridae 
(1) Binding to CD46 receptor, overexpressed 
on tumors 
Clinical 
phase I 
Myxoma  ds DNA 
Enveloped 
Rabbit 
Poxviridae 
(1) Replication in IFN-deficient tumor cells 
(2) High affinity to cells with activated Akt 
Pre-
clinical 
in vivo 
H1PV ss DNA 
Naked 
Rat 
Parvoviridae 
(1) Virus requires actively dividing cells in S 
phase for replication 
(2) Defects in PKR augment viral replication 
Clinical 
phase I 
SVV ss (+) 
RNA 
Naked 
Pig Picorna-
viridae 
(1) Strong tropism to neuroendocrine and 
solid pediatric tumors, possibly mediated 
through integrin >4 receptor binding 
Pre-
clinical 
in vitro 
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Table 2.4 Summary of the oncolytic viruses strain and types of studies that 
completed clinical trials in human brain cancer. For oncolytic NDV, 20 patients have 
been recruited in total (Zemp et al., 2010). 
 
Oncolytic viruses for gliomas in completed clinical trials—overview. 
 
Virus 
(strain) 
Genetics Study 
Type 
Patient 
number 
 
Dose/schedule/route of 
administration 
 
HSV-1 
(G207) 
 
g1-34.5 gene 
deletion lacZ 
insertion in 
UL39 
 
 
Phase I 
 
21 
 
1x10
6
 to 3x10
9
 pfu/single injection 
/intratumoral to enhancing area 
HSV-1 
(G207) 
g1-34.5 gene 
deletion lacZ 
insertion in 
UL39 
 
Phase I 9 1.5x10
8
 to 1x10
9
 pfu/intratumoral 
injections pre- and post-resection 
HSV-1 (HS-
1716) 
g1-34.5 gene 
deletion 
 
Phase I 9 1x10
3
 to 1x10
5
 pfu/single injection/ 
intratumoral 
HSV-1 (HS-
1716) 
g1-34.5 gene 
deletion 
 
Phase I 12 1x10
5
 pfu/single injection/ intratumoral 
HSV-1 (HS-
1716) 
g1-34.5 gene 
deletion 
 
Phase I 12 1x10
5
 pfu/single injection/ intratumoral 
AdV 
(ONYX-
015) 
 
E1B-55 kDa 
gene deletion 
Phase I 24 1x10
7
 to 1x10
10
 pfu/single injection/ 
tumor bed post-resection 
Reovirus Wildtype virus Phase I 12 1x10
7
 to 1x10
10
 pfu/single injection/ 
intratumoral 
 
NDV 
(MTH-
68/H) 
 
Attenuated NDV 
(mesogenic) 
Case 
report 1 
1 2x10
7
 to 2.5x10
8
 pfu/daily for years/ 
intravenous 
NDV 
(MTH-
68/H) 
 
Attenuated NDV 
(mesogenic) 
Case 
report 1 
4 2x10
7
 to 2.5x10
8
 pfu/daily for years/ 
intravenous 
NDV 
(MTH-
68/H) 
 
Attenuated NDV 
(mesogenic) 
Case 
report 1 
1 4x10
8
 pfu/daily for months/ alternating 
intravenous inhalational 
NDV 
(NDV-HUJ) 
Selected NDV 
(lentogenic) 
Phase I/II 14 0.1x10
9–11x109 IU/qd5; q1-2weeks, 3 
cycles of 55 11_109 IU/ intravenous 
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2.2 Newcastle Disease Virus (NDV) 
NDV is a highly contagious pathogen that affects avian species and causes 
severe economic losses to the poultry industry worldwide. NDV outbreaks were first 
reported in poultry from Java, Indonesia, followed by Newcastle-upon-Tyne in 1926 
(Seal et al., 2000; Zamarin and Palese, 2012). Eighteen NDV strains from four 
lineages were later identified and classified as either avirulent or virulent strains 
(Dortmans et al., 2011; Nidzworski et al., 2011). 
2.2.1 NDV virus taxonomy 
NDV is classified as a member of the Paramyxoviridae family of the 
Mononegavirales superfamily. This family is further divided into two subfamilies: 
the Paramyxovirinae and the Pneumovirinae (Seal et al., 2000; Dortmans et al., 
2011).  Other members of the Paramyxovirinae are Rubulavirus, Morbilivirus, 
Respirovirus, and Henipavirus. The genus of Avulavirus contains nine serotypes of 
avian paramyxoviruses (APMV-1-9); NDV represents type 1 (APMV-1). The 
disease potential of APMV-2 to -9 is not well known. APMV-2, -3, -6, and -7 have 
been associated with disease in turkeys, chickens and caged birds (Kumar et al., 
2011). 
Mumps, human parainfluenza, sendai, simian virus-5 and the recently 
emerged nipah and hendra viruses are important human viruses in this subfamily 
(Ravindra et al., 2009). These serotypes are summarized in Figure 2.2A. The 
paramyxoviruses comprise a large group of enveloped RNA viruses, some of which 
cause significant human and animal diseases. Virus particles are capsules built within 
infected cells that transmit infection from cell to cell and from host to host (Harrison 
et al., 2010).  
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A 
 
Family Subfamily Genus Species  
Paramyxoviridae Paramyxovirinae Rubulavirus  Mump virus, PIV5  
  Avulavirus NDV  
  Respirovirus Se Virus, Human PI Virus 3  
  Henipavirus He Virus, Ni Virus  
  Morbilivirus Me Virus  
 Pneumovirinae Pneumovirus Respiratory Syncytial Virus  
  Metapneumovirus HMPV, AMPV  
 
 
B 
 
 
C 
~15kb 
 
 
1.7kb 
 
 
1.4kb 
 
 
 
1.2kb 
 
 
 
1.8kb 
 
 
 
2.2kb 
 
 
 
6.5kb 
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L 
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Figure 2.2 Serotypes and molecular structure of paramyxovirus. A, the members of 
the paramyxoviridae family. B, schematic diagram and an electron microscopy 
picture of a paramyxovirus particle. C, a schematic diagram of NDV genome 
organization and viral transcript. The F and HN proteins project from the virion 
envelope to form spike-like instruments. The M protein is beneath the envelope. NP 
protein is tightly bound to the viral genome forming the nucleocapsid complex, and 
the L and P proteins are loosely bound to the nucleocapsid complex. (Veits et al., 
2006; Harrison et al., 2010).  
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2.2.2 NDV virus properties  
On the genomic basis, every oncolytic virus is characterized by several 
proteins that help to establish the infection of the host cells. The NDV is 
morphologically pleomorphic, often filamentous and may be polyploid (containing 
more than one genomic equivalent) with an envelope particle diameter between 100 
and 300 nm. The NDV genome consists of 15 kilobase pairs of non-segmented, 
single-stranded RNA, which code for 6 main structural proteins (Figure 2.2B and C 
page 22). These genes, nucleocapsid (NP), phosphorylation (P), matrix (M), fusion 
(F), hemagglutinin-neuraminidase (HN), and RNA-dependent RNA polymerase (L) 
proteins, are found in a 3’ NP-P-M-F-HN-L 5’ arrangement (Sinkovics and Horvath, 
2000; Schirrmacher and Fournier, 2009). 
The most abundant protein in NDV is the NP protein. This protein has a 
flexible helical structure with a diameter of approximately 18 nm and a height of 1 
μm, as observed by electron microscopy. The NP protein structure resembles 
classical morphology with spikes protruding from the central channel (Tan et al., 
2009). Each NP subunit consists of 489 amino acids with a molecular mass of 
approximately 53 kDa. Upon replication, NP subunits are associated with P and L 
proteins to encapsulate the viral genomic RNA into RNase-resistant nucleocapsid. 
This complex, instead of naked viral RNA, becomes the RNA template for the 
transcription and replication of the viral RNA genome (Harrison et al., 2010).  
The polycistronic phosphoprotein (P) gene codes for a protein of 395 amino 
acids with a calculated molecular weight of 42 kDa (Kumar et al., 2013). In the viral 
transcriptase complex, the P protein acts as a cofactor with dual functions: stabilizing 
the L protein and orienting the polymerase complex (P:L) on the formed NP:RNA 
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template for mRNA synthesis. In addition to the P protein, which is encoded by an 
unedited transcript of the P gene, NDV was also shown to edit its P gene mRNA to 
produce V and W proteins. The insertion of one G residue at the conserved editing 
site (UUUUUCCC, sense strand) will produce the V protein, while the insertion of 
two G residues at the same site will produce W protein. The real functions of these 
two non-structural proteins are yet to be identified, but some studies show that V 
protein significantly contributes to the virulence in avian cells (Huang et al., 2003; 
Jang et al., 2010). The V protein is known to have an inhibitory effect on the 
alpha/beta interferon response of the avian host (Farkas et al., 2009). 
The M gene codes for the matrix protein. It can be found between the 
nucleocapsid and the viral envelope proteins. The M protein, which consists of 371-
375 amino acids, is considered to be the central organizer of viral morphogenesis, 
due to its interactions with the cytoplasmic tails of the integral membrane proteins, 
the lipid bilayer, and the nucleocapsids. The self-association of M protein and its 
affinity for the nucleocapsid are the driving forces behind the formation of a budding 
virus particle (Andres Chang, 2012). For NDV, membrane deformation and vesicle 
budding have even been reconstituted in vitro using purified M protein and 
unilamellar vesicles, demonstrating that all of the activities necessary for inducing 
the curvature and fission of a membrane are contained within the M protein itself 
(Harrison et al., 2010). 
The F gene, an important determinant of NDV pathogenicity, consists of 540 
to 580 amino acids and is known as the fusion protein or fusion glycoprotein Type 1. 
Virulent and avirulent NDVs are characterized by the presence of multibasic or 
single basic residues, respectively, in the Fo cleavage site, as there is a difference in 
